Loading...
Please wait, while we are loading the content...
Similar Documents
Acquired hypermethylation of the P16INK4A promoter in abdominal paraganglioma: relation to adverse tumor phenotype and predisposing mutation
| Content Provider | Semantic Scholar |
|---|---|
| Author | Kiss, Nimrod B. Muth, Andreas Volker Andreasson, Adam Juhlin, Carl Christofer Geli, Janos Bäckdahl, Martin Höög, Anders Wängberg, Bo Nilsson, Ola Ahlman, Hakan B. J. Larsson, Catharina |
| Copyright Year | 2013 |
| Abstract | Recurrent alterations in promoter methylation of tumor suppressor genes (TSGs) and LINE1 (L1RE1) repeat elements were previously reported in pheochromocytoma and abdominal paraganglioma. This study was undertaken to explore CpG methylation abnormalities in an extended tumor panel and assess possible relationships between metastatic disease and mutation status. CpG methylation was quantified by bisulfite pyrosequencing for selected TSG promoters and LINE1 repeats. Methylation indices above normal reference were observed for DCR2 (TNFRSF10D), CDH1, P16 (CDKN2A), RARB, and RASSF1A. Z-scores for overall TSG, and individual TSG methylation levels, but not LINE1, were significantly correlated with metastatic disease, paraganglioma, disease predisposition, or outcome. Most strikingly, P16 hypermethylation was strongly associated with SDHB mutation as opposed to RET/MEN2, VHL/VHL, or NF1-related disease. Parallel analyses of constitutional, tumor, and metastasis DNA implicate an order of events where constitutional SDHB mutations are followed by TSG hypermethylation and 1p loss in primary tumors, later transferred to metastatic tissue. In the combined material, P16 hypermethylation was prevalent in SDHB-mutated samples and was associated with short disease-related survival. The findings verify the previously reported importance of P16 and other TSG hypermethylation in an independent tumor series. Furthermore, a constitutional SDHB mutation is proposed to predispose for an epigenetic tumor phenotype occurring before the emanation of clinically recognized malignancy. |
| Starting Page | 65 |
| Ending Page | 78 |
| Page Count | 14 |
| File Format | PDF HTM / HTML |
| Alternate Webpage(s) | https://erc.bioscientifica.com/downloadpdf/journals/erc/20/1/65.pdf |
| PubMed reference number | 23154831 |
| Alternate Webpage(s) | https://doi.org/10.1530/ERC-12-0267 |
| DOI | 10.1530/erc-12-0267 |
| Journal | Endocrine-related cancer |
| Volume Number | 20 |
| Language | English |
| Access Restriction | Open |
| Subject Keyword | Aortic Aneurysm, Abdominal CDKN2A gene Congenital Abnormality Cyclin-Dependent Kinase Inhibitor 2A, human Genes, Suppressor HIV 2 p16 Ab:PrThr:Pt:Ser:Ord:IB Hypermethylation Mutation Neoplasm Metastasis Neoplasms Paget's Disease, Mammary Paraganglioma Pheochromocytoma Protein methylation Pyrosequencing SDHB gene TNFRSF10D gene Tumor Suppressor Genes Von Hippel-Lindau Syndrome cancer-predisposing genes cytidylyl-3'-5'-guanosine hydrogen sulfite primary tumor promoter study of epigenetics |
| Content Type | Text |
| Resource Type | Article |
